|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 222 S. Riverside Plaza |
Address2 | Suite 1500 |
City | Chicago |
State | IL |
Zip Code | 60606 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 400348610-12
|
||||||||
|
6. House ID# 403510000
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Paul Melmeyer |
Date | 8/24/2022 3:38:58 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care.
Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 482 / S. 350, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients.
Advocated for robust funding of the national newborn screening program.
Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions.
Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions.
Advocated for the swift funding and implementation of the ACT for ALS Act (S.1813 and H.R.3537).
Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency.
Advocated for closure of the Medicaid coverage gap and the permanence of the Advanced Premium Tax Credits as part of the Build Back Better Act.
Advocated for a robust paid medical leave program.
Advocated for increased funding of home and community-based services (HCBS).
Supported the passage of the e Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706)
Advocated for reforms to the FDA Accelerated Approval program as part of the FDA user fee reauthorizations
Advocated for the creation of an FDA regulatory pathway for diagnostics, including lab-developed tests and invitro diagnostics.
Drafted recommendations to the Centers for Medicare and Medicaid Services on strengthening the Medicaid program.
Supported the Administrations efforts to withdraw the previous Administrations Public Charge rule.
Submitted recommendations to the Department of Health and Human Services on the implementation of section 504 of the Rehabilitation Act.
Supported greater appropriations for Consumer Assistance Programs
Advocated to the Architectural and Transportation Barriers Compliance Board (ATBCB) for amended Standards for Accessible Medical Diagnostic Equipment.
Advocated for the passage of the RARE Act (S. 4185) as part of the Senate FDA User Fee process.
Commented on fixing the ACA Family Glitch to the Treasury Department
Supported reforms to the HCPCS coding system.
Supported passage of the Ending the Diagnostic Odyssey Act
Advocated for the passage of the Accelerating Kids Access to Care Act
Advocated for certain provisions within the Cures 2.0 Legislation (H.R.6000)
Support the passage of the Precision Medicine for Children Act
Advocated for the passage of the HCBS Access Act
Supported the passage of the Stop the Wait Act (S. 3575 / H.R. 6583)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Treasury - Dept of, Labor - Dept of (DOL), Health Resources & Services Administration (HRSA), Natl Council on Disability
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AVI
16. Specific lobbying issues
Advocated for the passage of the Air Carrier Access Amendments Act (S.642, H.R.1893)
Advocated for further air travel access improvements for individuals with disabilities through regulation by FAA and DoT.
Submitted recommendations to the Senate Commerce Committee on accessible air travel within the FAA reauthorizations
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Federal Aviation Administration (FAA), Transportation - Dept of (DOT)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Advocated for robust funding for the Newborn Screening programs at the CDC, NIH, and HRSA
Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions.
Advocated for increased funding of the National Center for Advancing Translational Sciences (NCATS)
Advocated for the swift funding and implementation of the ACT for ALS Act (S.1813 and H.R.3537).
Advocated for increased funding of home and community-based services (HCBS).
Asked for greater appropriations to assist schools with providing services to individuals with disabilities.
Supported greater appropriations for Consumer Assistance Programs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Education - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Advocated in favor of robust appropriations funding for the National Institutes of Health, the Food and Drug Administration, the Health Resources and Services Administration, and the Centers for Disease Control and Prevention.
Advocated for greater appropriations for the National Center for Advancing Translational Sciences (NCATS)
Advocated for greater appropriations for the National Institutes of Health.
Advocated for appropriations for HHS, NIH, and FDA to implement the ACT for ALS.
Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 482 / S. 350, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients.
Supported the passage of the e Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706)
Advocated for reforms to the FDA Accelerated Approval program as part of the FDA user fee reauthorizations
Advocated for the creation of an FDA regulatory pathway for diagnostics, including lab-developed tests and invitro diagnostics.
Advocated for the passage of the RARE Act (S. 4185) as part of the Senate FDA User Fee process.
Advocated for certain provisions within the Cures 2.0 Legislation (H.R.6000)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions.
Supported additional coverage expansions by advocating that certain policies, such as permanent advanced premium tax credits and the closing of the Medicaid gap, are added to the Build Back Better Act.
Supported substantially increased funding to HCBS 1915 waivers.
Advocated for the passage of the STOP the WAIT Act (H.R.4386 and S.2496).
Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency.
Drafted recommendations to the Centers for Medicare and Medicaid Services on strengthening the Medicaid program.
Supported reforms to the HCPCS coding system.
Supported passage of the Ending the Diagnostic Odyssey Act
Advocated for the passage of the Accelerating Kids Access to Care Act
Advocated for certain provisions within the Cures 2.0 Legislation (H.R.6000)
Support the passage of the Precision Medicine for Children Act
Advocated for the passage of the HCBS Access Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions.
Advocated for permanent continuance of the advanced premium tax credits.
Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency.
Advocated for certain provisions within the Cures 2.0 Legislation (H.R.6000)
Supported passage of the Ending the Diagnostic Odyssey Act
Commented on fixing the ACA Family Glitch to the Treasury Department
Supported greater appropriations for Consumer Assistance Programs
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
Advocated for specific regulatory and administrative approaches to implementing the No Surprises Act.
Advocated for the Transformation to Competitive Integrated Employment Act (H.R.2373 and S.3238)
Advocated for the passage of the Disability Employment Incentive Act.
Advocated for a robust paid medical leave program.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Advocated for funding and implementation of the ACT for ALS, a law that should accelerate development of treatments for individuals with ALS and other neuromuscular diseases.
Advocated for the passage of the Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706)
Supported passage of the Ending the Diagnostic Odyssey Act
Advocated for the passage of the Accelerating Kids Access to Care Act
Advocated for certain provisions within the Cures 2.0 Legislation (H.R.6000)
Support the passage of the Precision Medicine for Children Act
Advocated for reforms to the FDA Accelerated Approval program as part of the FDA user fee reauthorizations
Advocated for the creation of an FDA regulatory pathway for diagnostics, including lab-developed tests and invitro diagnostics.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Advocated for permanency of the Advanced Premium Tax Credit for accessing quality, affordable health insurance.
Supported the Disability Employment Incentive Act, legislation that doubles incentives for businesses to hire individuals with disabilities.
Supported the enactment of the SSI Restoration Act.
Advocated for the permanent adoption of the changes to the Earned Income Tax Credit (EITC) and the Child Tax Credit (CTC).
Advocated for the passage of the SSI Savings Penalty Elimination Act (S. 4102)
Commented on fixing the ACA Family Glitch to the Treasury Department
Advocated for the enactment of the ABLE Age Adjustment Act
Advocated for the passage of the Supplemental Security Income Restoration Act (S. 2065 / HR 3763)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of, Social Security Administration (SSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRA
16. Specific lobbying issues
Advocated for the passage of the Air Carrier Access Amendments Act (S.642, H.R.1893)
Advocated for further air travel access improvements for individuals with disabilities through regulation by FAA and DoT.
Submitted recommendations to the Senate Commerce Committee on accessible air travel within the FAA reauthorizations
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, Federal Aviation Administration (FAA), U.S. HOUSE OF REPRESENTATIVES, Transportation - Dept of (DOT)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |